Trials / Recruiting

RecruitingNCT06680778

Pro-active Monitoring of Vital Signs in Oncology Patients Using a Smartwatch

The Use of Proa-active Monitoring by Measuring Vital Signs Using a Fitbit for a 3-month Period Before, During, and After Chemotherapy in Patients With Cancer

Status: Recruiting
Phase: —
Study type: Observational
Enrollment: 175 (estimated)

Sponsor: Erasmus Medical Center · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Detailed description

The goal of this single center prospective observational study is to determine the effect of chemotherapy on (the change in) vital parameters. The main question it aims to answer are: Can changes in vital parameters be measured by using a Fitbit in patients with cancer while undergoing chemotherapy. Participants will be asked to wear a Fitbit for the first two cycles of chemotherapy to evaluate the changes in vital parameters. Patients will start measuring in the week prior to the first cycle of chemotherapy, target is at least 4 to 7 days before initiation of chemotherapy. Patients were the Fitbit as much as possible, during day and night. Patients continuously carry the Fitbit during the first 3 months of systemic treatment, which tracks their vital signs. At the starting day of the next cycle of chemotherapy patients will have an appointment with one of the researchers to evaluate the use of the Fitbit. Furthermore, it will be checked if a patient has returned to their baseline vital signs.

Conditions

Interventions

Type	Name	Description
DEVICE	Proactive Monitoring	Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit

Timeline

Start date: 2025-07-01
Primary completion: 2025-11-01
Completion: 2025-12-31
First posted: 2024-11-08
Last updated: 2025-08-13

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06680778. Inclusion in this directory is not an endorsement.